Gastroenterology

This study validates criteria to identify patients with inflammatory bowel disease (IBD) at risk of worsening disease who may benefit from early treatment with advanced therapies.

Topline results from the phase 2b ANTHEM-UC study show all 3 doses of once-daily oral icotrokinra met the primary endpoint for clinical response.

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy received a second CRL as a frontline therapy for unresectable hepatocellular carcinoma (HCC).

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Celiac disease can lead to both disease-related and diet-induced vitamin deficiencies, making it crucial for patients to receive tailored nutritional management to ensure adequate nutritional intake.

Adults with irritable bowel syndrome (IBS) who smoke may face heightened challenges in quitting due to severe IBS symptoms and anxiety sensitivity, which increase perceived barriers and reinforce the belief that smoking helps relieve negative emotions.

The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, despite its good tolerability and low discontinuation rates, according to a systematic review.

Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments, increasing biosimilar adoption, and implementing policies that reduce financial disparities and improve long-term patient outcomes.

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.

Health care providers must recognize and address the high prevalence of anxiety in gastroenterology (GI) and hepatology outpatients, as its bidirectional relationship with chronic conditions can significantly impact both physical and emotional wellbeing, according to a global review.

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the highest risks among those with Crohn disease, ocular manifestations, or right-sided colonic involvement.

For pharmacists wondering whether bismuth quadruple therapy still reigns as the gold standard, the wait is over—the latest recommendations are here.

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.

Medical media is transforming pediatric gastroenterology and hepatology by boosting networking, research visibility, and education, but best practices are essential for clinical use.

Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The Crohn’s & Colitis Congress 2025 explored these access issues as well as the potential cardiovascular complications related to IBD therapies.

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network meta-analysis comparing biologics and small molecules.

The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition significantly increase the risk of gallstone disease in patients with Crohn disease.

The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for high- and moderate-risk patients.

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach to now include the full spectrum of inflammatory bowel disease.

Children born in spring or summer with a specific gene variant may have a higher risk of celiac disease and lower levels of a key protein, according to a study, potentially helping future research on autoimmune diseases.

A study found that patients with COVID-19 may have a higher risk of developing new gastrointestinal (GI) disorders compared with matched controls, highlighting the need for further research on long-term GI effects post COVID-19 infection.

Nationwide norovirus cases have recently increased, followed by an FDA warning for consumers to avoid oysters contaminated in a recent outbreak.

A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral therapy, may help alleviate persistent digestive symptoms and improve quality of life for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), alongside standard drug treatments.

The tablets are indicated for treatment of adults with chronic idiopathic constipation, with further research needed to assess efficacy and safety in children.

A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.